nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
|
Maiorano, B.A. |
|
|
7 |
5 |
p. |
artikel |
2 |
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
|
Capoluongo, E.D. |
|
|
7 |
5 |
p. |
artikel |
3 |
A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer
|
Yang, X. |
|
|
7 |
5 |
p. |
artikel |
4 |
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
|
Carlsson, G. |
|
|
7 |
5 |
p. |
artikel |
5 |
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
|
Chauca Strand, G. |
|
|
7 |
5 |
p. |
artikel |
6 |
Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
|
Debaudringhien, M. |
|
|
7 |
5 |
p. |
artikel |
7 |
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
|
Tomita, Y. |
|
|
7 |
5 |
p. |
artikel |
8 |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
|
Ciardiello, D. |
|
|
7 |
5 |
p. |
artikel |
9 |
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries
|
Soo, R. |
|
|
7 |
5 |
p. |
artikel |
10 |
Editorial Board
|
|
|
|
7 |
5 |
p. |
artikel |
11 |
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients
|
Jittla, P. |
|
|
7 |
5 |
p. |
artikel |
12 |
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
|
Wuerstlein, R. |
|
|
7 |
5 |
p. |
artikel |
13 |
Gender representation on editorial boards of leading oncology journals
|
Dai, N. |
|
|
7 |
5 |
p. |
artikel |
14 |
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
|
Aamdal, E. |
|
|
7 |
5 |
p. |
artikel |
15 |
How to read a next-generation sequencing report—what oncologists need to know
|
Schmid, S. |
|
|
7 |
5 |
p. |
artikel |
16 |
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
|
Su, E. |
|
|
7 |
5 |
p. |
artikel |
17 |
Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials
|
Filis, P. |
|
|
7 |
5 |
p. |
artikel |
18 |
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
|
Simonelli, M. |
|
|
7 |
5 |
p. |
artikel |
19 |
Letter re: Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
|
Zhang, J. |
|
|
7 |
5 |
p. |
artikel |
20 |
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
|
Boni, V. |
|
|
7 |
5 |
p. |
artikel |
21 |
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis ☆
|
Gulia, S. |
|
|
7 |
5 |
p. |
artikel |
22 |
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
|
Catenacci, D.V.T. |
|
|
7 |
5 |
p. |
artikel |
23 |
Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy
|
Gempt, J. |
|
|
7 |
5 |
p. |
artikel |
24 |
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF wt metastatic colorectal cancer ☆
|
Tabernero, J. |
|
|
7 |
5 |
p. |
artikel |
25 |
Multimodal survival prediction in advanced pancreatic cancer using machine learning
|
Keyl, J. |
|
|
7 |
5 |
p. |
artikel |
26 |
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors ☆
|
Park, H. |
|
|
7 |
5 |
p. |
artikel |
27 |
Recurrent or primary metastatic cervical cancer: current and future treatments
|
Gennigens, C. |
|
|
7 |
5 |
p. |
artikel |
28 |
Retrospective analysis of the prognostic implications of tumor spread through air spaces in lung adenocarcinoma patients treated with surgery
|
Gutierrez-Sainz, L. |
|
|
7 |
5 |
p. |
artikel |
29 |
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
|
Lasagna, A. |
|
|
7 |
5 |
p. |
artikel |
30 |
Table of Contents
|
|
|
|
7 |
5 |
p. |
artikel |
31 |
The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
|
Kim, C.M. |
|
|
7 |
5 |
p. |
artikel |
32 |
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
|
Hardenberg, M.C. |
|
|
7 |
5 |
p. |
artikel |
33 |
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
|
Le Tourneau, C. |
|
|
7 |
5 |
p. |
artikel |